Clinical Trials
76 trialsNCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT05255653 2026-05-15
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT07001748 2026-05-15
STOPGAP II
Eastern Cooperative Oncology Group
Phase 2/3 Recruiting
NCT07219238 2026-05-05
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Recruiting
NCT02839707 2026-05-04
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02502266 2026-04-29
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT07550205 2026-04-24
Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
Shanghai Municipal Hospital of Traditional Chinese Medicine
Phase 2/3 Not yet recruiting
NCT02758951 2026-03-24
CAIRO6
Catharina Ziekenhuis Eindhoven
Phase 2/3 Active not recruiting
NCT07472140 2026-03-16
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07472153 2026-03-16
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT07109414 2026-03-09
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Novita Pharmaceuticals, Inc.
Phase 2/3 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT07298642 2025-12-23
Extended-field Proton Therapy for Cervical Cancer
National Taiwan University Hospital
Phase 2/3 Recruiting
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting
NCT06866951 2025-12-16
A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial
Women's Hospital School Of Medicine Zhejiang University
Phase 2/3 Withdrawn
NCT05454358 2025-12-15
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University
Phase 2/3 Terminated
NCT06851663 2025-12-08
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Phase 2/3 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05381597 2025-11-28
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
Boston University
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770102 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT07177716 2025-09-17
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
L & L Bio Co., Ltd., Ningbo, China
Phase 2/3 Not yet recruiting
NCT06321068 2025-08-14
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
Phase 2/3 Terminated
NCT04159155 2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3 Terminated
NCT05316467 2025-08-11
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Fudan University
Phase 2/3 Recruiting
NCT05316935 2025-08-11
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Fudan University
Phase 2/3 Recruiting
NCT06379113 2025-08-11
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Fudan University
Phase 2/3 Recruiting
NCT02641639 2025-03-24
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Mateon Therapeutics
Phase 2/3 Terminated
NCT06791460 2025-03-18
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2/3 Recruiting
NCT06123884 2025-02-10
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Bio-Thera Solutions
Phase 2/3 Recruiting
NCT06755515 2025-01-01
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Enrolling by invitation
NCT01554397 2024-11-29
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
University of California, San Diego
Phase 2/3 Completed
NCT06288373 2024-10-30
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Phase 2/3 Recruiting
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT05797831 2024-05-02
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics, Inc.
Phase 2/3 Recruiting
NCT06227676 2024-04-12
NUTRITION; GYN
Cornell University
Phase 2/3 Completed
NCT06341907 2024-04-02
Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC
Second Affiliated Hospital of Wenzhou Medical University
Phase 2/3 Recruiting
NCT06211023 2024-01-18
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Not yet recruiting
NCT04864782 2024-01-12
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Terminated
NCT01506856 2023-09-15
iPocc
Gynecologic Oncology Trial & Investigation Consortium
Phase 2/3 Completed
NCT03458221 2023-04-18
STAPOVER
Gynaecologisch Oncologisch Centrum Zuid
Phase 2/3 Recruiting
NCT05489848 2022-08-05
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Fudan University
Phase 2/3 Not yet recruiting
NCT05203562 2022-07-12
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
Zagazig University
Phase 2/3 Unknown
NCT04795596 2022-04-15
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Menoufia University
Phase 2/3 Withdrawn
NCT03668639 2021-12-14
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Odense University Hospital
Phase 2/3 Unknown
NCT05149248 2021-12-08
CONDESA
Instituto Nacional de Salud Publica, Mexico
Phase 2/3 Completed
NCT02065687 2021-09-30
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
GOG Foundation
Phase 2/3 Unknown
NCT03463252 2021-09-13
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
West China Second University Hospital
Phase 2/3 Recruiting